A Phase 1 Placebo-controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Oral Doses Of Pf-04937319 In Adult Patients With Type 2 Diabetes Mellitus (t2dm)
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2017
At a glance
- Drugs PF 4937319 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 07 Jun 2017 Biomarkers information updated
- 25 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Mar 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.